Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
231. |
ECCT/09/09/02 | MAL-58 Study: Protocol no. 112745: SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS\' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN |
Principal Investigator(s) 1. LUCAS OTIENO TINA 2. MARY HAMEL Site(s) in Kenya 1. KEMRI-CDC, (Siaya county) 2. KEMRI-WRP (Kisumu county) |
24-06-2010 |
View |
232. |
ECCT/09/03/01 | REMoxTB A randomised placebo – controlled double blind trial comparing two treatment shortening regimens with the standard regimen (two months ethambutol, isoniazid, rifampicin and pyrazinamide followed by four months isoniazid and rifampicin) namely 1) two months moxifloxacin, isoniazid, rifampicin and pyrazinamide followed by two months moxifloxacin, isoniazid and rifampicin and 2) two months ethambutol, moxifloxacin, rifampicin and pyrazinamide followed by two months moxifloxacin and rifampicin for the treatment of adults with pulmonary tuberculosis |
Principal Investigator(s) 1. Evans Inyangala Amukoye Site(s) in Kenya Kibera D.O Health Centre |
01-07-2013 |
View |
233. |
ECCT/08/27/12 | MAL 55: A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection. Protocol No. 110021 - MAL 55 STUDY A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection, across diverse malaria transmission settings in Africa” |
Principal Investigator(s) 1. Dr. Mary Hamel 2. Dr. Patricia Njuguna 3. Dr. Walter Otieno Site(s) in Kenya 1. KEMRI - CDC RESEARCH INSTITUTION CENTRE, KISUMU (Kisumu county) 2. KEMRI-WELLCOME TRUST RESEARCH CENTER, KILIFI SITE (Kilifi county) 3. KEMRI-WALTERREED, RESEARCH CENTRE, KOMBEWA SITE (Kisumu county) |
07-12-2012 |
View |
234. |
ECCT/08/20/01 | Partners PrEP Study Parallel comparison of Tenofovir and Emtricitabine/Tenofovir pre exposure prophylaxis to prevent HIV-1 acquisition within HIV-1 discordant couples |
Principal Investigator(s) 1. James Njogu Kiarie 2. CAREY FARQUHAR, 3. Grace John Stewart Site(s) in Kenya 1. Nairobi (Nairobi City county) 2. Thika (Kiambu county) 3. Eldoret (Uasin Gishu county) 4. Kisumu (Kisumu county) |
09-10-2013 |
View |
235. |
ECCT/08/08/03 | Partners PrEP Study Parallel Comparison of Tenofovir and Emtricitabine/Tenofovir Pre-exposure Prophylaxis to Prevent HIV-1 Acquisition within HIV-1 Discordant Couples. |
Principal Investigator(s) 1. Prof. Connie Celum Site(s) in Kenya 1. Kenya- Eldoret (Uasin Gishu county) 2. Kenya – Nairobi (Nairobi City county) 3. Kenya – Kisumu (Kisumu county) 4. Kenya – Thika (Uasin Gishu county) |
12-11-2008 |
View |
236. |
ECCT/08/08/02 | Parallel Comparison of Tenofovir and Emtricitabine/tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition within HIV-1 Discordant Couples |
Principal Investigator(s) 1. Edwin Onyango Were Site(s) in Kenya 1. Eldoret Site (Uasin Gishu county) 2. Kisumu Site (Kisumu county) 3. Thika Site (Kiambu county) 4. Nairobi Site (Nairobi City county) |
25-07-2008 |
View |
237. |
ECCT/08/06/01 | PARTNERS PrEP Parallel Comparison of Tenofovir and Emtricitabine/tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition within HIV-1 Discordant Couples |
Principal Investigator(s) 1. Elizabeth Anne Bukusi Site(s) in Kenya 1. Kisumu site (Kisumu county) |
30-07-2008 |
View |
238. |
21/06/16 | VAT00008 A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older |
Principal Investigator(s) 1. Fredrick Sawe Site(s) in Kenya 1. Kenya Medical Research Institute, Kisumu Clinical Reseach Site (Kisumu county) 2. KEMRI/Walter Reed Project - Clinical Research Center, Kericho (Kericho county) 3. Ganjoni Clinic - University of Washington/University of Nairobi, Mombasa (Mombasa county) 4. Partners in Health Research and Development, Thika (Kiambu county) 5. KARGENO RESEARCH AND POLICY HUB (Kisumu county) 6. The Centre for Respiratory Diseases Research (CRDR), Kenya Medical Research Institute (KEMRI) (Nairobi City county) 7. KEMRI-USAMRD-A/K, Kombewa Clinical Research Center (Kisumu county) 8. Moi University Clinical Research Centre (MUCRC), Chandaria Cancer and Chronic Diseases Center (CCCDC) (Uasin Gishu county) 9. Aga Khan University Hospital (Nairobi City county) 10. KEMRI CCR-Butere County Hospital Site (Kakamega county) |
02-08-2021 |
View |